Deepika Jalota
Known title: SVP, Regulatory Affairs and QACIK: 0001825192
Associated companies
Transaction History
| PMVP | ▼ Sell | Open Market | 33,065 | $35K | 7/1/2025 | View on chart |
| PMVP | ▼ Sell | Open Market | 7,218 | $11K | 9/11/2024 | View on chart |
| PMVP | ▲ Buy | Grant | 95,555 | $0 | 1/18/2024 | View on chart |
| PMVP | ▼ Sell | Open Market | 4,104 | $27K | 9/15/2023 | View on chart |
| PMVP | ▲ Buy | Grant | 34,050 | $0 | 9/9/2022 | View on chart |
| PMVP | ▲ Buy | Option Exercise | 2,896 | $10K | 8/17/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 2,896 | $98K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
PMV Pharmaceuticals Adds Matt Eckler to Board
PMV Pharmaceuticals has appointed Matt Eckler, Ph.D., to its Board of Directors. This corporate update adds to the company's leadership team. The stock is currently trading near the top of its 52-week range, with an RSI of 69.0 indicating strong recent momentum.
PMV Pharmaceuticals Adds Matt Eckler to Board. PMV Pharmaceuticals has appointed Matt Eckler, Ph.D., to its Board of Directors. This corporate update adds to the company's leadership team. The stock is currently trading near the top of its 52-week range, with an RSI of 69.0 indicating strong recent momentum.